✦ LIBER ✦

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study

✍ Scribed by Irene M Ghobrial; Edie Weller; Ravi Vij; Nikhil C Munshi; Ranjit Banwait; Meghan Bagshaw; Robert Schlossman; Renee Leduc; Stacey Chuma; Janet Kunsman; Jacob Laubach; Andrzej J Jakubowiak; Patricia Maiso; Aldo Roccaro; Philippe Armand; Akari Dollard; Diane Warren; Brianna Harris; Tiffany Poon; Amy Sam; Scott Rodig; Kenneth C Anderson; Paul G Richardson

Book ID: 117785585
Publisher: The Lancet
Year: 2011
Tongue: English
Weight: 210 KB
Volume: 12
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(11)70028-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Tanespimycin and bortezomib combination

Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study

✍ Paul G. Richardson; Asher A. Chanan-Khan; Sagar Lonial; Amrita Y. Krishnan; Mich 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 382 KB

A phase I study of bortezomib in combina

A phase I study of bortezomib in combination with doxorubicin and intermediate-dose dexamethasone (iPAD therapy) for relapsed or refractory multiple myeloma

✍ Yasushi Takamatsu; Kazutaka Sunami; Hiroyuki Hata; Koji Nagafuji; Ilseung Choi; 📂 Article 📅 2010 🏛 Carden Jennings Publishing 🌐 English ⚖ 167 KB

Results from AMBER, a randomized phase 2

Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma

✍ Darrell White; Adetola Kassim; Birbal Bhaskar; Jing Yi; Karen Wamstad; Virginia 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 910 KB

Phase 2 study of arsenic trioxide in pat

Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma

✍ Mohamad A. Hussein; Mansoor Saleh; Farhad Ravandi; James Mason; Robert M. Rifkin 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB

An open-label, single-arm, phase 2 study

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

✍ Ravi Vij; David S. Siegel; Sundar Jagannath; Andrzej J. Jakubowiak; Alexander Ke 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 198 KB

Safety and efficacy of bortezomib and me

Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up

✍ James R. Berenson; Hank H. Yang; Robert A. Vescio; Youram Nassir; Russell Mapes; 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 164 KB